Valuation : Precigen, Inc.

Market Cap 2.54B 2.19B 2.06B 1.88B 3.52B 240B 3.53B 24.32B 9.44B 123B 9.55B 9.34B 397B P/E 2026 *
32.2x
P/E 2027 * 10.4x
Enterprise Value 2.54B 2.19B 2.06B 1.88B 3.52B 240B 3.53B 24.32B 9.44B 123B 9.55B 9.34B 397B EV / Sales 2026 *
10.9x
EV / Sales 2027 * 5.59x
Free-Float
87.38%
Yield 2026 *
-
Yield 2027 * -
1 day-0.56%
1 week+2.16%
Current month+2.45%
1 month+8.73%
3 months+83.94%
6 months+100.00%
Current year+69.86%
1 week 6.6
Extreme 6.6016
7.27
1 month 6.08
Extreme 6.08
7.72
Current year 3.04
Extreme 3.04
7.72
1 year 2.99
Extreme 2.99
7.72
3 years 0.65
Extreme 0.6513
7.72
5 years 0.65
Extreme 0.6513
7.72
10 years 0.65
Extreme 0.6513
32.9
Manager TitleAgeSince
Chief Executive Officer 64 01/01/2020
Director of Finance/CFO 64 01/10/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 01/02/2008
Director/Board Member 78 01/02/2008
Director/Board Member 70 28/11/2011
Date Insider Type Main position Quantity % Market Cap. Importance
26/08/26 Sell

Director

-185,000 0.0620%
25/08/26 Exercice

Executive/Senior Manager

237,498 0.0796%
25/08/26 Exercice

Chief Operating Officer

46,026 0.0154%
Change 5-day change 1-year change 3-year change Capi.($)
-0.56%+2.16%+55.70%+292.27% 2.54B
-0.88%-2.15%+54.71%+106.31% 1,024B
-1.15%+2.68%+53.97%+71.50% 663B
-1.44%+0.38%+20.40%+73.05% 453B
+0.14%-0.47%+29.49%+38.56% 352B
-1.33%+4.72%+24.69%+45.55% 304B
-1.15%+0.30%-1.49%+12.31% 252B
-1.55%+1.11%+56.10%+70.32% 236B
-0.88%+1.15%-17.09%-54.39% 206B
-0.15%+3.65%+33.90%+96.99% 187B
Average -0.94%+1.20%+31.04%+75.25% 368.09B
Weighted average by Cap. -1.10%+0.55%+36.64%+66.38%

Financials

2026 *2027 *
Net sales 233M 200M 189M 172M 322M 22B 323M 2.23B 865M 11.29B 875M 856M 36.36B 454M 391M 368M 336M 629M 42.9B 630M 4.35B 1.69B 22.01B 1.71B 1.67B 70.91B
Net income 83.08M 71.49M 67.27M 61.45M 115M 7.84B 115M 795M 308M 4.02B 312M 305M 12.97B 257M 221M 208M 190M 356M 24.28B 357M 2.46B 954M 12.45B 965M 944M 40.12B
Net Debt - -
Logo Precigen, Inc.
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Employees
160
Date Price Change Volume
04/09/26 $7.100 -0.56% 2,192,987
03/09/26 $7.140 +1.85% 2,188,672
02/09/26 $7.010 +2.19% 2,638,059
01/09/26 $6.860 -1.01% 2,806,113
31/08/26 $6.930 -0.29% 4,135,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
7.100USD
Average target price
14.50USD
Spread / Average Target
+104.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PGEN Stock